Effect of particle formulation on dry powder inhalation efficiency

Current Pharmaceutical Design

Volumn 16, Issue 21, 2010, Pages 2377-2387

  Hassan, Meer Saiful ^a   Lau, Raymond ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Drug formulation; Dry powder inhalation; Particle characteristics; Particle interactions; Pulmonary drug delivery

Indexed keywords

ANTIBIOTIC AGENT; CHITOSAN; DOXORUBICIN; DRUG CARRIER; INSULIN; LACTOSE; MANNITOL; NANOPARTICLE; OVALBUMIN; POLYGLACTIN; RIFAMPICIN;

DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY POWDER; PARTICLE SIZE; PHYSICAL CHEMISTRY; POWDER INHALER; PRIORITY JOURNAL; REVIEW; SPRAY DRYING; WETTABILITY;

ADMINISTRATION, INHALATION; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; HUMANS; NANOPARTICLES; PARTICLE SIZE; POWDERS; TREATMENT OUTCOME;

EID: 77955643465     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791920423     Document Type: Review

References (209)

1. LaVan DA, McGuire T, Langer R. Small-scale systems for in vivo drug delivery. Nat Biotechnol 2003; 21: 1184-91.
2. O'Callaghan C, Nerbrink O, Vidgren MT. The history of inhaled drug therapy. In: Bisgaard H, O'Callaghan C, Smaldone GC, Eds. Drug delivery to the lung. New York: Marcel Dekker, Inc. 2001.
3. Scheuch G, Kohlhaeufl MJ, Brand P, et al. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv Drug Deliv Rev 2006; 58: 996-1008.
4. Huang YY, Wang CH. Pulmonary delivery of insulin by liposomal carriers. J Control Release 2006; 113: 9-14.
5. Agu RU, Ugwoke MI, Armand M, et al. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res 2001; 2: 198-209.
6. Brain JD. Inhalation, deposition, and fate of insulin and other therapeutic proteins. Diabetes Technol Therap 2007; 9: S4-15.
7. Patton JS, Bukar J, Nagarajan S. Inhaled insulin. Adv Drug Deliv Rev 1999; 35: 235-47.
8. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007; 6: 67-74.
9. Altiere R, Thompson D. Physiology and pharmacology of the airways. In: Hickey A, Ed. Inhalation aerosols. New York: Marcel Dekker 1996; pp. 233-72.
10. Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev 1996; 19: 3-36.
11. Touw DJ, Brimicombe RW, Hodson ME, et al. Inhalation of antibiotics in cystic-fibrosis Eur Respir J 1995; 8: 1594-604.
12. Georgitis JW. The 1997 asthma management guidelines and therapeutic issues relating to the treatment of asthma. Chest 1999; 115: 210-7.
13. Gelperina S, Kisich K, Iseman MD, et al. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 2005; 172: 1487-90.
14. Bennett WD, Brown JS, Zeman KL, et al. Targeting delivery of aerosols to different lung regions. J Aerosol Med 2002; 15: 179-88.
15. Murer B. Targeted therapy in non-small cell lung cancer: a commentary. Arch Pathol Lab Med 2008; 132: 1573-5.
16. Young PM, Chan Hk, Chiou H, et al. The influence of mechanical processing of dry powder inhaler carriers on drug aerosolization performance. J Pharm Sci 2007; 96: 1331-41.
17. Gonda I. Targeting by deposition. In: Hickey AJ, Ed. Pharmaceutical inhalation aerosol technology. New York: Marcel Dekker, Inc. 2004; pp. 65-88.
18. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003; 56: 588-99.
19. Koshkina NV, Knight V, Gilbert BE, et al. Improved respiratory delivery of the anticancer drugs, camptothecin and paclitaxel, with 5% CO2-enriched air: pharmacokinetic studies. Cancer Chemotherapy Pharmacol 2001; 47: 451-6.
20. Wolff RK, Dorato MA. Toxicology testing of inhaled pharmaceutical aerosols. Crit Rev Toxicol 1993; 23: 343-69.
21. Borm PJA, Kreyling W. Toxicological hazards of inhaled nanoparticles- Potential implications for drug delivery. J Nanosci Nanotechnol 2004; 4: 521-31.
22. Smith IJ. The challenge of reformulation. J Aerosol Med 1995; 8: S19-S27.
23. Smith IJ, Parry-Billings M. The inhalers of the future? A review of dry powder devices on the market today. Pulmonary Pharmacol Ther 2003; 16: 79-95.
24. Atkins P. Dry powder inhalers: an overview. Respir Care 2005; 50: 1304-12.
25. Laube BL. The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care 2005; 50: 1161-76.
26. Newman SP. Dry powder inhalers for optimal drug delivery. Expert Opin Biol Ther 2004; 4: 23-33.
27. Frijlink HW, Boer AHD. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 2004; 1: 67-86.
28. LiCalsi C, Christensen T, Bennett JV, et al. Dry powder inhalation as a potential delivery method for vaccines. Vaccine 1999; 17: 1796-803.
29. Johnson KA. Preparation of peptide and protein powders for inhalation. Adv Drug Deliv Rev 1997; 26: 3-15.
30. Everard ML, Devadason SG, Sunderland VB, et al. An alternative aerosol delivery system for amiloride. Thorax 1995; 50: 517-9.
31. Bosquillon C, Préat V, Vanbever R. Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats. J Control Release 2004; 96: 233-44.
32. Rubin BK. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J Aerosol Med Pulmonary Drug Deliv 2008; 21: 71-6.
33. Newhouse MT, Hirst PH, Duddu SP, et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest 2003; 124: 360-6.
34. Cheer SM, Waugh J, Noble S. Inhaled tobramycin (TOBI ®)-A review of its use in the management of pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs 2003; 63: 2501-20.
35. Daniher DI, Zhu J. Dry powder platform for pulmonary drug delivery. Particuology 2008; 6: 225-38.
36. Shoyele SA. Engineering protein particles for pulmonary drug delivery. Drug Deliv Syst 2008: 149-60.
37. Chew NYK, Chan HK. Use of solid corrugated particles to enhance powder aerosol performance. Pharm Res 2001; 18: 1570-7.
38. Hickey AJ, Concessio NM. Flow properties of selected pharmaceutical powders from a vibrating spatula. Particle Particle Syst Characterization 1994; 11: 457-62.
39. Louey M, Van Oort M, Hickey A. Aerosol dispersion of respirable particles in narrow size distributions produced by jet-milling and spray-drying techniques. Pharm Res 2004; 21: 1200-6.
40. Louey M, Van Oort M, Hickey A. Aerosol dispersion of respirable particles in narrow size distributions using drug-alone and lactoseblend formulations. Pharm Res 2004; 21: 1207-13.
41. Adi S, Adi H, Tang P, et al. Micro-particle corrugation, adhesion and inhalation aerosol efficiency. Eur J Pharm Sci 2008; 35: 12-8.
42. Hinds WC. Aerosol technology: properties, behavior, and measurement of airborne particles. 2nd ed. New York: John Weily & Sons 1999.
43. Mitsakou C, Helmis C, Housiadas C. Eulerian modelling of lung deposition with sectional representation of aerosol dynamics. J Aerosol Sci 2005; 36: 75-94.
44. Heyder J. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thoracic Soc 2004; 1: 315-20.
45. Dolovich M, Newhouse M. Aerosols. Generation, methods of administration, and therapeutic applications in asthma. In: Middleton EJ, Reed C, Ellis E, Adkinson NJ, Yunginger J, Busse W, Eds. Allergy Principles and practice. St Louis: Mosby Year Book, Inc. 1993; pp. 712-39.
46. Heyder J. Particle transport onto human airway surfaces. Eur J Respiratory Diseases 1982; 63(Suppl 119): 29-50.
47. Heyder J, Rudolf G. Mathematical models of particle deposition in the human respiratory tract. J Aerosol Sci 1984; 15: 697.
48. Stahlhofen W, Gebhart J, Heyder J. Experimental determination of the regional deposition of aerosol particles in the human respiratory tract. Am Indus Hyg Assoc J 1980; 41: 385-98.
49. Byron PR. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci 1986; 75: 433-8.
50. Heyder J, Gebhart J, Rudolf G, et al. Deposition of particles in the human respiratory tract in the size range 0.005-15 μm. J Aerosol Sci 1986; 17: 811.
51. Visser J. Van der Waals and other cohesive forces affecting powder fluidization. Powder Technol 1989; 58: 1-10.
52. Visser J. Particle adhesion and removal: a review. Particulate Sci Technol 1995; 13: 169-96.
53. Davies CN. Particle-fluid interaction. J Aerosol Sci 1979; 10: 477-513.
54. Crowder TM, Rosati JA, Schroeter JD, et al. Fundamental effects of particle morphology on lung delivery: predictions of stokes' law and the particular relevance to dry powder inhaler formulation and development. Pharm Res 2002; 19: 239-45.
55. Edwards DA. Delivery of biological agents by aerosols. AIChE J 2002; 48: 2-6.
56. Lippmann M, Timbell V. Particle loading in the human lung- Human experience and implications for exposure limits. J Aerosol Med 1991: 155-68.
57. Fults KA, Miller IF, Hickey AJ. Effect of particle morphology on emitted dose of fatty acid-treated disodium cromoglycate powder aerosols. Pharm Develop Technol 1997; 2: 67-79.
58. Esmen NA. Adhesion and aerodynamic resuspension of fibrous particles. J Environ Eng 1996; 122: 379-83.
59. Otsuka A, Iida K, Danjo K, et al. Measurement of the adhesive forces between particles of powdered materials and a glass substrate by means of the impact separation method 3. Effect of particle shape and surface asperity. Chem Pharm Bull 1988; 36: 741-9.
60. Harris RL, Fraser DA. A model for deposition of fibers in the human respiratory system. Am Ind Hyg Assoc J 1976; 37: 73-89.
61. Gradon L, Podgorski A. Experimental study on fibrous particle deposition in the human nasal cast. J Aerosol Sci 1992; 23: S469-72.
62. Martonen TB, Johnson DL. Aerodynamic size classification of fibers with aerosol centrifuges. Particulate Sci Technol 1990; 8: 37-53.
63. Chan H-K, Gonda I. Aerodynamic properties of elongated particles of cromoglycic acid. J Aerosol Sci 1989; 20: 157-68.
64. ® by polymorphic transformation to needle-like crystals (β-form). Pharm Res 2002; 19: 1439-45.
65. Balásházy I, Martonen TB, Hofmann W. Fiber deposition in airway bifurcations. J Aerosol Med 1990; 3: 243-60.
66. Hassan MS, Lau R. Pollen shape particles for pulmonary drug delivery: In vitro study of flow and deposition properties. 13th Int Conf Biomed Eng 2009; 23: 1434-7.
67. Hassan M, Lau R. Effect of particle shape on dry particle inhalation: Study of flowability, aerosolization, and deposition properties. AAPS PharmSciTech 2009; 10: 1252-62.
68. Dunbar C, Scheuch G, Sommerer K, et al. In vitro and in vivo dose delivery characteristics of large porous particles for inhalation. Int J Pharm 2002; 245: 179-89.
69. Musante CJ, Schroeter JD, Rosati JA, et al. Factors affecting the deposition of inhaled porous drug particles. J Pharm Sci 2002; 91: 1580-90.
70. Ungaro F, d'Emmanuele di villa Bianca R, Giovino C, et al. Insulin- loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs. J Control Release 2009; 135: 25-34.
71. Giovagnoli S, Blasi P, Schoubben A, et al. Preparation of large porous biodegradable microspheres by using a simple doubleemulsion method for capreomycin sulfate pulmonary delivery. Int J Pharmaceutics 2007; 333: 103-11.
72. Garcia-Contreras L, Fiegel J, Telko MJ, et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother 2007; 51: 2830-6.
73. Tsapis N, Bennett D, Jackson B, et al. Trojan particles: Large porous carriers of nanoparticles for drug delivery. Proc Nat Acad Sci USA 2002; 99: 12001-5.
74. Vanbever R, Mintzes JD, Wang J, et al. Formulation and physical characterization of large porous particles for inhalation. Pharm Res 1999; 16: 1735-42.
75. Edwards DA, Hanes J, Caponetti G, et al. Large porous particles for pulmonary drug delivery. Science 1997; 276: 1868.
76. Edwards DA, Ben-Jebria A, Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol 1998; 85: 379-85.
77. Adi H, Traini D, Chan HK, et al. The influence of drug morphology on aerosolisation efficiency of dry powder inhaler formulations. J Pharm Sci 2008; 97: 2780-8.
78. Chew NYK, Tang P, Chan HK, et al. How much particle surface corrugation is sufficient to improve aerosol performance of powders? Pharm Res 2005; 22: 148-52.
79. Kawashima Y, Serigano T, Hino T, et al. Design of inhalation dry powder of pranlukast hydrate to improve dispersibility by the surface modification with light anhydrous silicic acid (AEROSIL 200). Int J Pharmaceutics 1998; 173: 243-51.
80. Kawashima Y, Serigano T, Hino T, et al. A new powder design method to improve inhalation efficiency of pranlukast hydrate dry powder aerosols by surface modification with hydroxypropylmethylcellulose phthalate nanospheres. Pharm Res 1998; 15: 1748-52.
81. Philip VA, Mehta RC, Mazumder MK, et al. Effect of surface treatment on the respirable fractions of PLGA microspheres formulated for dry powder inhalers. Int J Pharm 1997; 151: 165-74.
82. Braun MA, Oschmann R, Schmidt PC. Influence of excipients and storage humidity on the deposition of disodium cromoglycate (DSCG) in the twin impinger. Int J Pharm 1996; 135: 53-62.
83. Morrow PE. Factors determining hygroscopic aerosol deposition in airways. Physiol Rev 1986; 66: 330-76.
84. Martonen TB. Analytical model of hygroscopic particle behavior in human airways. Bull Math Biol 1982; 44: 425-42.
85. Hickey AJ, Gonda I, Irwin WJ, et al. The effect of hydrophobic coating upon the behavior of a hygroscopic aerosol powder in an environment of controlled temperature and relative humidity. J Pharm Sci 1990; 79: 1009-14.
86. Islam N, Stewart P, Larson I, et al. Effect of carrier size on the dispersion of salmeterol xinafoate from interactive mixtures. J Pharm Sci 2004; 93: 1030-8.
87. Kawashima Y, Serigano T, Hino T, et al. Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrate. Int J Pharm 1998; 172: 179-88.
88. Larhrib H, Zeng XM, Martin GP, et al. The use of different grades of lactose as a carrier for aerosolised salbutamol sulphate. Int J Pharm 1999; 191: 1-14.
89. Steckel H, Markefka P, te Wierik H, et al. Effect of milling and sieving on functionality of dry powder inhalation products. Int J Pharm 2006; 309: 51-9.
90. Larhrib H, Cespi M, Dyas MA, et al. Engineered carrier with a long time of flight (TOF) to improve drug delivery from dry powder inhalation aerosols. Drug Deliv Lung (DDL) 2006; 17: 304-7.
91. Larhrib H, Martin GP, Prime D, et al. Characterisation and deposition studies of engineered lactose crystals with potential for use as a carrier for aerosolised salbutamol sulfate from dry powder inhalers. Eur J Pharm Sci 2003; 19: 211-21.
92. Larhrib H, Martin GP, Marriott C, et al. The influence of carrier and drug morphology on drug delivery from dry powder formulations. Int J Pharm 2003; 257: 283-96.
93. Steckel H, Bolzen N. Alternative sugars as potential carriers for dry powder inhalations. Int J Pharm 2004; 270: 297-306.
94. Podczeck F. The influence of particle size distribution and surface roughness of carrier particles on the in vitro properties of dry powder inhalations. Aerosol Sci Technol 1999; 31: 301-21.
95. Zimon AD. Adhesion of Dust and Powder. New York: Consultants Bureau 1982.
96. Corn M. Adhesion of particles in Aerosol Science. New York: Academic Press 1966.
97. Young PM, Edge S, Traini D, et al. The influence of dose on the performance of dry powder inhalation systems. Int J Pharm 2005; 296: 26-33.
98. Flament MP, Leterme P, Gayot A. The influence of carrier roughness on adhesion, content uniformity and the in vitro deposition of terbutaline sulphate from dry powder inhalers. Int J Pharm 2004; 275: 201-9.
99. Zeng XM, Martin GP, Marriott C, et al. Lactose as a carrier in dry powder formulations: The influence of surface characteristics on drug delivery. J Pharm Sci 2001; 90: 1424-34.
100. Iida K, Hayakawa Y, Okamoto H, et al. Evaluation of flow properties of dry powder inhalation of salbutamol sulfate with lactose carrier. Chem Pharm Bull 2001; 49 1326.
101. Steckel H, Müller BW. In vitro evaluation of dry powder inhalers II: Influence of carrier particle size and concentration on in vitro deposition. Int J Pharm 1997; 154: 31-7.
102. French DL, Edwards DA, Niven RW. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J Aerosol Sci 1996; 27: 769-83.
103. Zeng XM, Martin GP, Marriott C, et al. The influence of carrier morphology on drug delivery by dry powder inhalers. Int J Pharm 2000; 200: 93-106.
104. Islam N, Stewart P, Larson I, et al. Surface roughness contribution to the adhesion force distribution of salmeterol xinafoate on lactose carriers by atomic force microscopy. J Pharm Sci 2005; 94: 1500-11.
105. Li Q, Rudolph V, Peukert W. London-van der Waals adhesiveness of rough particles. Powder Technol 2006; 161: 248-55.
106. Iida K, Inagaki Y, Todo H, et al. Effects of surface processing of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate. Chem Pharm Bull 2004; 52: 938-42.
107. Iida K, Hayakawa Y, Okamoto H, et al. Influence of storage humidity on the in vitro inhalation properties of salbutamol sulfate dry powder with surface covered lactose carrier. Chem Pharm Bull 2004; 52: 444-6.
108. Hassan MS, Lau R. Inhalation performance of pollen-shape carrier in dry powder formulation with different drug mixing ratios: Comparison with lactose carrier. Int J Pharm 2010; 386: 6-14.
109. Hassan MS, Lau R. Flow behavior and deposition study of pollen shape carrier particles in an idealized inhalation path model. Particuology 2010; 8: 51-9.
110. Hassan MS, Lau R. Feasibility study of pollen-shape drug carriers in dry powder inhalation. J Pharm Sci 2009; 99: 1309-21.
111. Adi H, Larson I, J. PS. Influence of the polydispersity of the added fine lactose on the dispersion of salmeterol xinafoate from mixtures for inhalation. Eur J Pharm Sci 2009; 36: 265-74.
112. Guchardi R, Frei M, John E, et al. Influence of fine lactose and magnesium stearate on low dose dry powder inhaler formulations. Int J Pharm 2008; 348: 10-7.
113. Lai Wah C, Liang Theng L, Paul WSH. Immobilization of fine particles on lactose carrier by precision coating and its effect on the performance of dry powder formulations. J Pharm Sci 2003; 92: 975-84.
114. Louey MD, Stewart PJ. Particle interactions involved in aerosol dispersion of ternary interactive mixtures. Pharm Res 2002; 19: 1524-31.
115. Zeng XM, Martin GP, Tee SK, et al. The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitro. Int J Pharm 1998; 176: 99-110.
116. Begat P, Morton DAV, Shur J, et al. The role of force control agents in high-dose dry powder inhaler formulations. J Pharm Sci 2009; 98: 2770-83.
117. Begat P, Price R, Harris H, et al. The influence of force control agents on the cohesive-adhesive balance in dry powder inhaler formulations. KONA Powder Particle J 2005; 23: 109-21.
118. Louey MD, Razia S, Stewart PJ. Influence of physico-chemical carrier properties on the in vitro aerosol deposition from interactive mixtures. Int J Pharm 2003; 252: 87-98.
119. Zeng XM, Pandhal KH, Martin GP. The influence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols. Int J Pharm 2000; 197: 41-52.
120. Zeng XM, Martin GP, Tee SK, et al. Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation. Int J Pharm 1999; 182: 133-44.
121. Tee SK, Marriott C, Zeng XM, et al. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate. Int J Pharm 2000; 208: 111-23.
122. Lucas P, Anderson K, Staniforth JN. Protein deposition from dry powder inhalers: Fine particle multiplets as performance modifiers. Pharm Res 1998; 15: 562-9.
123. Adi H, Larson I, Chiou H, et al. Agglomerate strength and dispersion of salmeterol xinafoate from powder mixtures for inhalation. Pharm Res 2006; 23: 2556-65.
124. Hu G, Otaki H, Watanuki K. Optimization of grinding performance of tumbling ball mill. JSME Int J Ser C-Mechan Syst Mach Elements Manufact 2001; 44: 267-74.
125. Drogemeier R, Leschonski K. Ultra fine grinding in a two stage rotor impact mill. Int J Mineral Proc 1996; 44-5: 485-95.
126. Cheng YS, Marshall TC, Henderson RF, et al. Use of a jet mill for dispersing dry powder for inhalation studies. Am Ind Hyg Assoc J 1985; 46: 449-54.
127. Tong HHY, Yu Shekunov B, York P, et al. Characterization of two polymorphs of salmeterol xinafoate crystallized from supercritical fluids. Pharm Res 2001; 18: 852-8.
128. Steckel H, Pichert L, Müller BW. Influence of process parameters in the ASES process on particle properties of budesonide for pulmonary delivery. Eur J Pharm Biopharm 2004; 57: 507-12.
129. Steckel H, Thies J, Müller BW. Micronizing of steroids for pulmonary delivery by supercritical carbon dioxide. Int J Pharm 1997; 152: 99-110.
130. Bakhbakhi Y, Charpentier PA, Rohani S. Experimental study of the GAS process for producing microparticles of beclomethasone-17,21-dipropionate suitable for pulmonary delivery. Int J Pharm 2006; 309: 71-80.
131. Velaga SP, Berger R, Carlfors J. Supercritical fluids crystallization of budesonide and flunisolide. Pharm Res 2002; 19: 1564-71.
132. Debenedetti PG, Tom JW, Kwauk X, et al. Rapid expansion of supercritical solutions (RESS)- fundamentals and applications. Fluid Phase Equilibria 1993; 82: 311-21.
133. Shekunov BY. Production of powders for respiratory drug delivery. In: York P, Kompella UB, Shekunov BY, Eds. Supercritical fluid technology for drug product development. New York: Marcel Dekker 2004; pp. 247-82.
134. Steckel H, Brandes HG. A novel spray-drying technique to produce low density particles for pulmonary delivery. Int J Pharm 2004; 278: 187-95.
135. Chawla A, Taylor KMG, Newton JM, et al. Production of spray dried salbutamol sulphate for use in dry powder aerosol formulation. Int J Pharm 1994; 108: 233-40.
136. Maa YF, Zhao L, Payne LG, et al. Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application. J Pharm Sci 2003; 92: 319-32.
137. Kim JC, Kim JD. Preparation by spray drying of amphotericin Bphospholipid composite particles and their anticellular activity. Drug Deliv 2001; 8: 143-7.
138. Bosquillon C, Lombry C, Préat V, et al. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J Control Release 2001; 70: 329-39.
139. Millqvist-Fureby A, Malmsten M, Bergenståhl B. Spray-drying of trypsin-surface characterisation and activity preservation. Int J Pharm 1999; 188: 243-53.
140. Pilcer G, Vanderbist F, Amighi K. Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery. Int J Pharm 2009; 365: 162-9.
141. Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res 2008; 25: 999-1022.
142. Yuh-Fun M, Phuong-Anh TN, Selena WH. Spray-drying of airliquid interface sensitive recombinant human growth hormone. J Pharm Sci 1998; 87: 152-9.
143. Tajber L, Corrigan OI, Healy AM. Spray drying of budesonide, formoterol fumarate and their composites-II. Statistical factorial design and in vitro deposition properties. Int J Pharm 2009; 367: 86-96.
144. Tajber L, Corrigan DO, Corrigan OI, et al. Spray drying of budesonide, formoterol fumarate and their composites-I. Physicochemical characterisation. Int J Pharm 2009; 367: 79-85.
145. Sivadas N, O'Rourke D, Tobin A, et al. A comparative study of a range of polymeric microspheres as potential carriers for the inhalation of proteins. Int J Pharm 2008; 358: 159-67.
146. Learoyd TP, Burrows JL, French E, et al. Chitosan-based spraydried respirable powders for sustained delivery of terbutaline sulfate. Eur J Pharm Biopharm 2008; 68: 224-34.
147. Zijlstra GS, Hinrichs WLJ, Boer AHd, et al. The role of particle engineering in relation to formulation and de-agglomeration principle in the development of a dry powder formulation for inhalation of cetrorelix. Eur J Pharm Sci 2004; 23: 139-49.
148. Najafabadi A, Gilani K, Barghi M, et al. The effect of vehicle on physical properties and aerosolisation behaviour of disodium cromoglycate microparticles spray dried alone or with L-leucine. Int J Pharm 2004; 285: 97-108.
149. Gilani K, Rouholamini Najafabadi A, Barghi M, et al. Aerosolisation of beclomethasone dipropionate using spray dried lactose/ polyethylene glycol carriers. Eur J Pharm Biopharm 2004; 58: 595-606.
150. Rabbani NR, Seville PC. The influence of formulation components on the aerosolisation properties of spray-dried powders. J Control Release 2005; 110: 130-40.
151. Vidgrén MT, Vidgrén PA, Paronen TP. Comparison of physical and inhalation properties of spray-dried and mechanically micronized disodium cromoglycate. Int J Pharm 1987; 35: 139-44.
152. Seville PC, Learoyd TP, Li HY, et al. Amino acid-modified spraydried powders with enhanced aerosolisation properties for pulmonary drug delivery. Powder Technol 2007; 178: 40-50.
153. Andya JD, Maa YF, Costantino HR, et al. The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody. Pharm Res 1999; 16: 350-8.
154. Li HY, Seville PC, Williamson IJ, et al. The use of amino acids to enhance the aerosolisation of spray-dried powders for pulmonary gene therapy. J Gene Med 2005; 7: 343-53.
155. Bosquillon C, Rouxhet PG, Ahimou F, et al. Aerosolization properties, surface composition and physical state of spray-dried protein powders. J Control Release 2004; 99: 357-67.
156. Li HY, Neill H, Innocent R, et al. Enhanced dispersibility and deposition of spray-dried powders for pulmonary gene therapy. J Drug Target 2003; 11: 425-32.
157. Minne A, Boireau H, Horta MJ, et al. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients. Eur J Pharm Biopharm 2008; 70: 839-44.
158. David LB, Chatan C, Cheryl LMS, et al. Trileucine improves aerosol performance and stability of spray-dried powders for inhalation. J Pharm Sci 2008; 97: 287-302.
159. Arakawa T, Tsumoto K, Kita Y, et al. Biotechnology applications of amino acids in protein purification and formulations. Amino Acids 2007; 33: 587-605.
160. Gavini E, Hegge AB, Rassu G, et al. Nasal administration of carbamazepine using chitosan microspheres: in vitro/in vivo studies. Int J Pharm 2006; 307: 9-15.
161. Martinac A, Filipovic-Grcic J, Voinovich D, et al. Development and bioadhesive properties of chitosan-ethylcellulose microspheres for nasal delivery. Int J Pharm 2005; 291: 69-77.
162. Surendrakumar K, Martyn GP, Hodgers ECM, et al. Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J Control Release 2003; 91: 385-94.
163. Cook RO, Pannu RK, Kellaway IW. Novel sustained release microspheres for pulmonary drug delivery. J Control Release 2005; 104: 79-90.
164. Hallworth GW. Inhalation composition containing lactose pellets. Patent. US, 2001; 6,183,782.
165. Sung J, Padilla D, Garcia-Contreras L, et al. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res 2009; 26: 1847-55.
166. Plumley C, Gorman EM, El-Gendy N, et al. Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy. Int J Pharm 2009; 369: 136-43.
167. Oyarzun-Ampuero FA, Brea J, Loza MI, et al. Chitosan-hyaluronic acid nanoparticles loaded with heparin for the treatment of asthma. Int J Pharm 2009; 381: 122-9.
168. Nashwa EG, Eric MG, Eric JM, et al. Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution. J Pharm Sci 2009; 98: 2731-46.
169. Peek LJ, Roberts L, Berkland C. Poly(D,L-lactide-co-glycolide) nanoparticle agglomerates as carriers in dry powder aerosol formulation of proteins. Langmuir 2008; 24(17): 9775-83.
170. Bailey MM, Gorman EM, Munson EJ, et al. Pure insulin nanoparticle agglomerates for pulmonary delivery. Langmuir 2008; 24: 13614-20.
171. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol 2007; 25: 563-70.
172. Shi L, Plumley CJ, Berkland C. Biodegradable nanoparticle flocculates for dry powder aerosol formulation. Langmuir 2007; 23: 10897-901.
173. Sepassi S, Goodwin DJ, Drake AF, et al. Effect of polymer molecular weight on the production of drug nanoparticles. J Pharm Sci 2007; 96: 2655-66.
174. Hadinoto K, Zhu K, Tan RBH. Drug release study of large hollow nanoparticulate aggregates carrier particles for pulmonary delivery. Int J Pharm 2007; 341: 195-206.
175. Hadinoto K, Phanapavudhikul P, Kewu Z, et al. Dry powder aerosol delivery of large hollow nanoparticulate aggregates as prospective carriers of nanoparticulate drugs: effects of phospholipids. Int J Pharm 2007; 333: 187-98.
176. Grenha A, Grainger CI, Dailey LA, et al. Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro. Eur J Pharm Sci 2007; 31: 73-84.
177. Hadinoto K, Phanapavudhikul P, Kewu Z, et al. Novel formulation of large hollow nanoparticles aggregates as potential carriers in inhaled delivery of nanoparticulate drugs. Ind Eng Chem Res 2006; 45: 3697-706.
178. Azarmi S, Tao X, Chen H, et al. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int J Pharm 2006; 319: 155-61.
179. Zahoor A, Sharma S, Khuller GK. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrobial Agents 2005; 26: 298-303.
180. Labhasetwar V. Nanotechnology for drug and gene therapy: the importance of understanding molecular mechanisms of delivery. Curr Opin Biotechnol 2005; 16: 674-80.
181. Grenha A, Seijo B, Remuñán-López C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci 2005; 25: 427-37.
182. Sham JOH, Zhang Y, Finlay WH, et al. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int J Pharm 2004; 269: 457-67.
183. Rao GCS, Kumar MS, Mathivanan N, et al. Nanosuspensions as the most promising approach in nanoparticulate drug delivery systems. Pharmazie 2004; 59: 5-9.
184. Moore MN. Biocomplexity: the post-genome challenge in ecotoxicology. Aquatic Toxicol 2002; 59: 1-15.
185. Huang M, Ma Z, Khor E, et al. Uptake of FITC-chitosan nanoparticles by A549 cells. Pharm Res 2002; 19: 1488-94.
186. Russell-Jones GJ, Veitch H, Arthur L. Lectin-mediated transport of nanoparticles across Caco-2 and OK cells. Int J Pharm 1999; 190: 165-74.
187. Ghirardelli R, Bonasoro F, Porta C, et al. Identification of particular epithelial areas and cells that transport polypeptide-coated nanoparticles in the nasal respiratory mucosa of the rabbit. Biochim Biophys Acta (BBA)-Biomembr 1999; 1416: 39-47.
188. Kreuter J. Nanoparticle-based drug delivery systems. J Control Release 1991; 16: 169-76.
189. Kreuter J. Nanoparticles and microparticles for drug and vaccine delivery. J Anantomy 1996; 189: 503-5.
190. Schürch S, Gehr P, Im Hof V, et al. Surfactant displaces particles toward the epithelium in airways and alveoli. Respir Physiol 1990; 80: 17-32.
191. Chono S, Tanino T, Seki T, et al. Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes. J Drug Target 2006; 14: 557-66.
192. Couvreur P, Vauthier C. Polyalkylcyanoacrylate nanoparticles as drug carrier: present state and perspectives. J Control Release 1991; 17: 187-98.
193. Löbenberg R, Araujo L, Kreuter J. Body distribution of azidothymidine bound to nanoparticles after oral administration. Eur J Pharm Biopharm 1997; 44: 127-32.
194. Lobenberg R, Kreuter J. Macrophage targeting of azidothymidine: A promising strategy for AIDS therapy. AIDS Res Hum Retroviruses 1996; 12: 1706-15.
195. Shargel L, Yu A. Applied biopharmaceutics & pharmacokinetics. 4th ed. New York: McGraw Hill 1999.
196. Kreuter J. Drug targeting with nanoparticles. Eur J Drug Metab Pharmacokin 1994; 19: 253-6.
197. Geiser M, Schurch S, Gehr P. Influence of surface chemistry and topography of particles on their immersion into the lung's surfacelining layer. J Appl Physiol 2003; 94: 1793-801.
198. Oberdorster G. Toxicokinetics and effects of fibrous and nonfibrous particles. Inhalation Toxicol 2002; 14: 29-56.
199. Oberdorster G, Sharp Z, Atudorei V, et al. Extrapulmonary translocation of ultrafine carbon particles following whole-body inhalation exposure of rats. J Toxicol Environ Health-Part A 2002; 65: 1531-43.
200. Lindfors L, Skantze P, Skantze U, et al. Amorphous drug nanosuspensions. 3. Particle dissolution and crystal growth. Langmuir 2007; 23: 9866-74.
201. Kesisoglou F, Panmai S, Wu Y. Nanosizing-Oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 2007; 59: 631-44.
202. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004; 3: 785-96.
203. Oberdorster G, Ferin J, Lehnert BE. Correlation between particlesize, in vivo particle resistance, and lung injury. Environ Health Perspect 1994; 102: 173-9.
204. Hoet P, Bruske-Hohlfeld I, Salata O. Nanoparticles-known and unknown health risks. J NanoBiotechnol 2004; 2: 12.
205. Nel A, Xia T, Madler L, et al. Toxic potential of materials at the nanolevel. Science 2006; 311: 622-7.
206. Oberdörster G, Oberdörster E, Oberdörster J. Nanotoxicology: An emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005; 113: 823-39.
207. Ali J, Ali M, Baboota S, et al. Potential of Nanoparticulate Drug Delivery Systems by Intranasal Administration. Curr Pharm Des 2010; 16(14): 1644-53.
208. Berridge MS, Lee Z, Heald DL. Regional distribution and kinetics of inhaled pharmaceuticals. Curr Pharm Des 2000; 6(16): 1631-51.
209. Heinemann L, Pfutzner A, Heise T. Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery. Curr Pharm Des 2001; 7(14): 1327-51.